133 related articles for article (PubMed ID: 38462823)
1. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
Itzler R; Buckner TW; Leebeek FWG; Miller J; Recht M; Drelich D; Monahan PE; Pipe SW
Haemophilia; 2024 May; 30(3):709-719. PubMed ID: 38462823
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
3. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
[TBL] [Abstract][Full Text] [Related]
4. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
[TBL] [Abstract][Full Text] [Related]
5. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
[TBL] [Abstract][Full Text] [Related]
7. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
[TBL] [Abstract][Full Text] [Related]
8. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
9. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.
von Drygalski A; Gomez E; Giermasz A; Castaman G; Key NS; Lattimore SU; Leebeek FWG; Miesbach WA; Recht M; Gut R; Dolmetsch R; Monahan PE; Le Quellec S; Pipe SW
Blood Adv; 2023 Oct; 7(19):5671-5679. PubMed ID: 36490302
[TBL] [Abstract][Full Text] [Related]
10. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
11. Etranacogene Dezaparvovec: First Approval.
Heo YA
Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
[TBL] [Abstract][Full Text] [Related]
12. No difference in quality of life between persons with severe haemophilia A and B.
Kihlberg K; Baghaei F; Bruzelius M; Funding E; Andre Holme P; Lassila R; Nummi V; Ranta S; Gretenkort Andersson N; Berntorp E; Astermark J
Haemophilia; 2023 Jul; 29(4):987-996. PubMed ID: 36791275
[TBL] [Abstract][Full Text] [Related]
13. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
14. Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.
Windyga J; Lin VW; Epstein JD; Ito D; Xiong Y; Abbuehl BE; Ramirez JH
Haemophilia; 2014 May; 20(3):362-8. PubMed ID: 24251442
[TBL] [Abstract][Full Text] [Related]
15. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
16. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
[TBL] [Abstract][Full Text] [Related]
17. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
[TBL] [Abstract][Full Text] [Related]
18. Measurement properties of the Haem-A-QoL in haemophilia clinical trials.
von Mackensen S; Eldar-Lissai A; Auguste P; Krishnan S; von Maltzahn R; Yu R; Wyrwich KW
Haemophilia; 2017 May; 23(3):383-391. PubMed ID: 28026074
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
O'Mahony B; Dunn AL; Leavitt AD; Peyvandi F; Ozelo MC; Mahlangu J; Peerlinck K; Wang JD; Lowe GC; Tan CW; Giermasz A; Tran H; Khoo TL; Cockrell E; Pepperell D; Chambost H; López Fernández MF; Kazmi R; Majerus E; Skinner MW; Klamroth R; Quinn J; Yu H; Wong WY; Robinson TM; Pipe SW
J Thromb Haemost; 2023 Dec; 21(12):3450-3462. PubMed ID: 37678546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
